a wholly owned subsidiary of La Jolla Pharmaceutical Company





Until recently, technological challenges significantly limited the potential for developing tetracycline compounds. Our proprietary technology, developed at Harvard University and enhanced by Tetraphase, overcomes these challenges, making it possible to synthesize an unprecedented number of structurally diverse tetracycline-based drug candidates.


Research and Discovery

Tetracyclines are among the most commonly used classes of antibiotics and have been proven safe and effective in more than 50 years of clinical use. Previously, all tetracyclines were “semisynthetic,” that is, primarily obtained by fermentation, purified, and modified for clinical use. The nature of this process, however, markedly limited potential modifications so that only a narrow range of tetracyclines have been synthesized.

Our proprietary chemistry technology, based on a published breakthrough process, represented a significant innovation in the creation of tetracycline drugs. It allowed us to chemically modify many positions on the tetracycline core structure, making it possible to create and pursue a wider variety of novel tetracycline compounds for the treatment of infections that are resistant to existing tetracyclines and other antibiotic classes.


Please enter a valid email address.


Please enter a valid email address.

Share information about Tetraphase


Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.